Navigation Links
Periods in Biological Technology

GenVec Reports Second Quarter 2009 Financial Results

... Revenues for the three-month and six-month periods ended June 30, 2009 were $3.8 million and $7.6 ... year periods. For the three-month and six-month periods ended June 30, 2009 we experienced decreases in ... to the scope of work performed in the current periods as compared to the prior year. Also contributing ...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

... TAXUS may have stabilized after several quarterly periods of significant decline. Royalty revenue for the ... device from patients more easily, or after longer periods of time have passed as compared to existing ... interim financial statements for the three-month periods ended June 30, 2009, and 2008. Full unaudited ...

Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results

... The per share amount for the three and six month periods of 2009 includes the effect of the issuance of ... The per share amounts for three and six month periods of 2008 include only the effect of the 2008 ... share amounts between the 2009 and 2008 periods presented. ...

CuraGen Reports Second Quarter 2009 Financial Results

... approval. During the three and six month periods ended June 30, 2009, CuraGen utilized $3.8 ... and $0.7 million for the three and six month periods ended June 30, 2009, respectively. As of June ... and $1.6 million for the three and six month periods ended June 30, 2009, respectively. CuraGen ...

Sunesis Reports Financial Results for the Second Quarter 2009

... to $2.6 million and $4.9 million for the same periods in 2008. Sunesis recognized $2.0 million in the ... milestone referred to above. Revenues in the 2008 periods were primarily related to research funding under ... from $8.3 million and $17.0 million for the same periods in 2008. The decreases were primarily due to ...

Vasogen Announces Second Quarter 2009 Results

... with $7.6 million and $11.0 million for the same periods in 2008. The $1.4 million of net cash used in ... 2009 has decreased when compared with the same periods in 2008 due to the significant expenditures that were incurred during the 2008 periods to implement the restructuring that was announced ...

Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update

... RESULTS FROM OPERATIONS Three and nine month periods ended April 30, 2009 compared to the same period ... respectively, for the three and nine month periods ended April 30, 2009, for a loss per common share ... In the comparative three and nine month periods ended April 30, 2008, the Company recorded a loss ...

Publication of Shire plc's Annual Report 2008

... Rules which applies in respect of accounting periods commencing after January 20, 2007, Appendix to ... distraction of senior management for prolonged periods of time, significant defense costs and ... its key scientific and management personnel for periods of one year or less. The loss of such personnel, ...

Helix BioPharma Announces Q2 2009 Financial Results

... Results from Operations Three and six month periods ended January 31, 2009 compared to the same periods in the previous year Loss for the period ... respectively, for the three and six month periods ended January 31, 2009, for a loss per common ...

OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009

... $4.1 million, respectively, in the corresponding periods of 2007. The increases in 2008 were primarily due ... $3.5 million, respectively, in the corresponding periods of 2007. The increase for the fourth quarter of ... $11.5 million, respectively, in the corresponding periods of 2007. The increase for the fourth quarter of ...

ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results

... Operating income decreased in both comparative periods primarily due to increased amortization expense, ... 14.0 percent, respectively, compared to the same periods in 2007. The cost of sales for the three ... consistent, respectively, as compared to the same periods in 2007. For the three months and year ended ...

Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals

... to estimate the costs to be incurred in those periods and believes those costs do not reflect the ... of ongoing operating results against prior periods and against our internally developed targets. We ... to estimate the costs to be incurred in those periods and believes those costs do not reflect the ...

Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results

... for the same period in 2007. The decrease in both periods primarily reflects revenues from Amgen related to ... the for same period in 2007. The increase in both periods is due primarily to increased costs associated ... were $2.3 million for both of the three-month periods ended September 30, 2008 and 2007. For the nine ...

Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year

... been presented as discontinued operations for all periods presented in the Condensed ... Quarterly periods 4Q08 ... Quarterly periods ...

Oncothyreon reports third quarter 2008 financial results

... and $4.0 million for the three and nine month periods ended September 30, 2008, compared to $1.1 million and $1.9 million for the comparable periods in 2007. The increase in total revenue for the ... per basic and diluted share, for the comparable periods in 2007. Expenses for the three and nine ...

ev3 Inc. Reports Third Quarter 2008 Financial Results

... comparable U.S. GAAP measures for the respective periods can be found immediately following the detail of ... comparable U.S. GAAP measures for the respective periods can be found in tables later in this release ... comparable U.S. GAAP measures for the respective periods can be found in the tables below. In addition, an ...

Thoratec Reports 44 Percent Increase in Third Quarter Revenues

... facilitate comparisons of results for current periods and guidance for future periods with our historical operating results, and assist ... income statement for the three and nine month periods ending 2008 and 2007. ...

VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007

... in the second quarter of 2008 related to periods prior to 2008. VNUS' balance sheet at September ... in the second quarter of 2008 related to periods prior to 2008. VNUS believes Adjusted EBITDA and ... $(6,464) Calculation of Fully Taxed EPS for periods with net income: Income before provision for ...

Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009

... million, respectively, for the corresponding periods of Fiscal 2008. This represents increases of 195% and 200% over the respective periods of Fiscal 2008. Pre-tax income grew to $12.3 ... million, respectively, for the corresponding periods of Fiscal 2008, reflecting increases of 22% and ...

Neuralstem Reports Second Quarter Financial Results and Highlights

... or $(0.10) per share, for the comparable periods in 2007. The increase in net loss year to year ... and development expenses for the six month periods ending June 30, 2008 and 2007 were $2,832,572 and ... and administrative expenses for the six month periods ending June 30, 2008 and 2007 were $2,401,877 and ...

Genaera Corporation Announces Second Quarter Financial Results

... financial results for the three- and six-month periods ended June 30, 2008. The net loss for ... development expenses for the three- and six-month periods ended June 30, 2008 were $3.5 million and $7.4 ... and $6.6 million, respectively, for the same periods in 2007. The increase was primarily due to ...

Isis Reports Financial Results and Highlights for Second Quarter of 2008

... $17.3 million and $35.8 million during the same periods in 2007. On a GAAP basis, Isis recorded a loss ... to $19.7 million and $40.6 million for the same periods in 2007. The significant improvement in ... higher than the revenue from the same periods in 2007 of $3.8 million and $6.3 million as ...

GeneNews Announces Second Quarter Results

... (year-to-date - $6.2 million) for the same periods last year. Research and development expenses in ... (year-to-date - $4.4 million) for the same periods last year. General and administrative expenses ... (year-to-date - $1.3) for the corresponding periods in the previous year. The net loss for the ...

SemBioSys announces second quarter 2008 financial and operational results

... Total revenue for the three and six-month periods ended June 30, 2008 was $62,207 and $272,234 ... $459,407 and $1,002,195 for the corresponding periods in 2007. The difference is due mainly to a ... Total expenditures for the three and six-month periods ended June 30, 2008 were $6,542,258 and ...

Oncolytics Biotech Inc. Announces 2008 Second Quarter Results

... highlights for the three and six month periods ended June 30, 2008. "Oncolytics experienced a ... evaluable patients experienced stable disease for periods ranging from two to more than ten, 28-day ... patients experiencing stable disease for periods ranging from two to more than twelve, 28-day ...

Beckman Coulter Announces Second Quarter 2008 Results

... the associated recurring revenue in future periods positions the company for reliable and ... to estimate the costs to be incurred in those periods and believes those costs do not reflect ... of ongoing operating results against prior periods and against our internally developed targets. We ...

Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results

... Net Sales periods Ending June 30, 2008 and 2007 ... Key Product Line Sales periods Ending June 30, 2008 and 2007 ... by US and International Three-Month periods Ending June 30, 2008 and 2007 ...

ARIUS announces second quarter fiscal 2008 financial results

... May 31, 2007. This increase in net loss for both periods is primarily the result of higher research ... same period in fiscal 2007. The increase for both periods was primarily the result of the recognition of ... same period in fiscal 2007. The decrease for both periods was primarily the result of lower average cash ...

Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008

... financial results for the three and nine month periods ended April 30, 2008. "During the quarter, we ... RESULTS FROM OPERATIONS Three and nine month periods ended April 30, 2008 compared to the same period ... and $4,309,000 for the three and nine month periods ended April 30, 2008, respectively, for a loss ...

Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter

... respectively. For the comparable periods of fiscal 2007, the amounts were $2.9 million and ... million, and $49.5 million, in the comparable periods of fiscal 2007, respectively. Income tax ... per share for fiscal 2008. For the comparable periods of fiscal 2007, the amounts were a net loss of ...

Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance

... core operating results and trends for the periods presented. Non-GAAP financial measures are ... core operating results and trends for the periods presented. Non-GAAP financial measures are not ... relative to the operating results for the periods presented, these items have been excluded ...

Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook

... Net Sales periods Ending March 31, 2008 and 2007 ... Key Product Line Sales periods Ending March 31, 2008 and 2007 ... Sales by US and International periods Ending March 31, 2008 and 2007 ...

Renovis Reports Fourth Quarter and Full Year 2007 Financial Results

... million and $10.4 million in the corresponding periods in 2006. All of the revenue earned in the year ... to $7.4 million and $28.1 million during the same periods in 2006. The decrease in the fourth quarter of ... to $3.9 million and $15.6 million during the same periods of 2006. The decrease in the quarter ended ...

Helix BioPharma reports Q2 2008 highlights, financial results

... months ended January 31, 2008, compared to same periods in previous year Total revenue was negatively ... in Canada for both the three and six month periods ended January 31, 2008. Overall expenditures were ... respectively, for the three and six month periods ended January 31, 2008, for a loss per common ...

ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results

... (or $23.1 million), respectively, for the same periods in 2006. The change in gross margin for the ... to $6.1 million and $23.8 million during the same periods of 2006. The increase in research and development ... million and $37.4 million for the corresponding periods in 2006. The 2007 increase primarily resulted ...

United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results

... ended December 31, 2007, over the same periods in 2006, primarily as a result of a stock option ... 2007 and 2006, respectively. For the three-month periods ended December 31, 2007 and 2006, we recognized a ... of net income and EBITDASO for the three-month periods ended December 31, 2007 and 2006, and for ...

Favrille Reports Fourth Quarter and Year End 2007 Financial Results

... $40.5 million, or $1.49 per share, for the same periods in 2006. (Logo: ... $7.7 million and $31.1 million for the same periods in 2006. The increase is primarily due to ... $2.9 million and $11.2 million for the same periods in 2006. The decrease for the quarter ...

Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark.

... (all percentage comparisons are to comparable periods in 2006): -- Q4 2007 Sales Set New Quarterly ... diluted EPS for the quarter and year-to-date periods can be found on pages 4 and 11, respectively. -- ... (all percentage comparisons are to comparable periods in 2006): A reconciliation of reported and ...

Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History

... facilitate comparisons of results for current periods and guidance for future periods with our historical operating results, and assist ... statement for the three months and twelve months periods ending in 2007 and 2006. ...

KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis

... consolidated financial statements for the fiscal periods 2004 through 2006. Due to the pending ... period. Net revenue growth in the current year periods was due to increased volume in the Company's pain ... of the Company's financial statements for fiscal periods from 1996 through 2006 and for the quarter ended ...
Other Contents
(Date:8/22/2014)... 2014 Research ... the addition of the  "Biometrics Market ... their offering.       (Logo: ... technology that helps in the identification ... or behavioral features. It involves verification ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information ... the University of California, Riverside in its 2014 list ... our times." , To generate the list, the company ... researchers whose published work has had enormous impact. , ... 3,200 individuals who published the greatest number of highly ...
(Date:8/22/2014)... La Jolla, CA Research presented at the ... therapy being developed by Hera Therapeutics Inc. combats ... that cause 70 percent of all cervical cancer. ... models, HTI-1968 blocked the replication of HPV-16, HPV-18 ... Ph.D. and Thomas Broker, Ph.D., who presented the ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
(Date:8/23/2014)... Dallas, Texas (PRWEB) August 23, 2014 ... deterioration of the function of the myocardium (the ... heart failure; common symptoms are dyspnea (breathlessness) and ... cardiomyopathy are often at risk of dangerous forms ... The most common form of cardiomyopathy is dilated ...
(Date:8/23/2014)... "I have heard female patients complain about making ... an inventor from Lake Stevens, Wash. "In order to ... up with this urine-collection aid." , He developed the ... from women more easily. The accessory prevents messes. It ... The invention improves sanitation and prevents the spread of ...
(Date:8/23/2014)... 2014 "Many men refuse to touch ... up getting covered in urine and spit," said an ... bathroom situations, I came up with this hygienic device." ... a man raises the toilet seat before urinating. The ... This reduces contact with dirt and germs. The accessory ...
(Date:8/23/2014)... 2014 The report “Polycarbonate Resin ... Forecasts to 2018” defines and segments the global ... the global revenue and consumption. It also identifies ... resin market with analysis of trends, opportunities, burning ... consumption and revenues are forecasted on the basis ...
(Date:8/23/2014)... 2014 GranuFlo lawsuit ( http://www.thegranuflolawsuit.com ... NaturaLyte dialysis concentrate recall continue to mount in ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... the U.S. Judicial Panel on Multidistrict Litigation (JPML) ... pending in the proceeding. In July, the Panel ...
Breaking Medicine News(10 mins):Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 2Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 3Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 4Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 4
Other TagsOther Tags